NYSE:NVO
Related posts
Nervous markets await NvidiaThis summary was created by AI, based on 40 opinions in the last 12 months.
Novo-Nordisk is facing challenges in the competitive landscape of obesity and diabetes drugs, particularly against Eli Lilly, which is gaining market share. Experts indicate that while NVO's stock has declined significantly, with a current valuation around 19x to 22x forward PE and expected growth rates of 14-25%, the company remains a leader in weight-loss treatments. The company benefits from strong brand recognition and ongoing demand for its obesity drugs like Ozempic and Wegovy. However, analysts express concerns about the heavy reliance on a few major drugs and the potential impact of increasing competition in the weight-loss sector. Overall, while there is a belief in long-term growth prospects due to rising obesity rates, current market conditions and short-term volatility present caution for investors considering new positions.
It was the biggest European company last year. This and LLY are growing double digits and the market is growing double digits. Has owned NVO 9 years and trimmed it 7 times, and this is the first time he's bought more, on weakness. Obesity and diabetes are not going away.
(Analysts’ price target is $64.51)The key drug is its weight-loss one, a class of drugs he believes in and feels will be the biggest drug on the world ever, worth $120 billion in 2030. Huge growth. These drugs offer cardio benefits in addition to weight-loss. He prefers LLY.
He's owned this since 2015, trimming 7 times (that's just good risk management). Markets were pushed well ahead of themselves in 2024, and then we saw a big retraction. Fast money has come out of this name. Down ~60%, growing double digits, 16x forward PE (vs. LLY at 43x forward PE). LLY is really strong in the US, but not outside.
At this valuation, a no-brainer. Again, you make $$ when you buy not when you sell. He's going to wait and see what happens with the CEO position.
Deal to get off injectables and over to tablets. Went up too far, too fast, now has fallen. LLY has 60% of revenues in US, NVO has 60% outside US. Concern is that LLY's product helps people lose more weight. But Type 2 diabetics are still growing worldwide, especially in China and India.
Trades ~16x PE, lowest it's been in almost 20 years. He's buying more. The value is there, and the company's not getting any credit for its weight-loss drug. Don't hold both LLY and NVO, as it's correlation risk.
Is -17% this year and -42% the past year. It went too far too fast. He's been buying more on the way down, because obesity won't change, so their weight-loss drug will keep selling. Tariffs: NVO has facilities in the US already. 60% of revenues are outside North America (vs. Eli Lilly's 60% within US). To extend patent protection, a pharma company just needs to change its formula every 3 years to extend the patent protection. There will be competition, but NVO has brand recognition and scale.
Its stock decline is not unique in this market: most growth companies have been hit very very hard, in one of the sharpest sell-offs we have seen in some time. NVO is 19X earnings now, with a 2.90% dividend. The balance sheet is fine and good growth is still expected over the next two years. We would be comfortable owning this and riding out the current market malaise, which will end one of these days (weeks, or months).
Unlock Premium - Try 5i Free
Sentiment's pretty rough on this name. Fairly cheap at 22x forward PE, 18% earnings growth. Regulatory scrutiny. Lost a bit of market share to LLY (which he still holds). Below 200-day MA, which is moving down. Growth of GLP-1 drugs is there, so he's keeping an eye on it for future.
Novo-Nordisk is a American stock, trading under the symbol NVO-N on the New York Stock Exchange (NVO). It is usually referred to as NYSE:NVO or NVO-N
In the last year, 27 stock analysts published opinions about NVO-N. 16 analysts recommended to BUY the stock. 8 analysts recommended to SELL the stock. The latest stock analyst recommendation is . Read the latest stock experts' ratings for Novo-Nordisk.
Novo-Nordisk was recommended as a Top Pick by on . Read the latest stock experts ratings for Novo-Nordisk.
Earnings reports or recent company news can cause the stock price to drop. Read stock experts’ recommendations for help on deciding if you should buy, sell or hold the stock.
27 stock analysts on Stockchase covered Novo-Nordisk In the last year. It is a trending stock that is worth watching.
On 2025-09-05, Novo-Nordisk (NVO-N) stock closed at a price of $55.23.
Falling rapidly after a great run. Price is below 200-day MA. Valuations look somewhat attractive, but sentiment remains pretty rough. 14x forward PE for 8-10% growth. Guided lower for the year.
Great long-term catalysts, as Wegovy shows strength in treating obesity, diabetes, heart attacks, stroke, and liver disease. But it's all about patent cliffs, pricing risks, and competition.